secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122300
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO Q3 net loss $59.6M; cash $278.6M; RGX-202 pivotal trial initiation expected this month
--------------------------------------------------------------------------------

- Net loss of $59.6M ($1.17 EPS) vs $61.9M ($1.41 EPS) in Q3 2023.
- Revenue $24.2M, down from $28.9M, driven by lower Zolgensma royalties ($23.9M vs $28.4M).
- Cash, cash equivalents and marketable securities $278.6M as of Sep 30, 2024.
- RGX-202 pivotal trial initiation and first functional data expected November 2024.
- BLA submission for RGX-121 (MPS II) initiated, expected completion Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000095017024122300/0000950170-24-122300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000095017024122300/rgnx-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer